Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCVIDDOXIL Regimen in Newly Diagnosed Peripheral T-Cell Lymphoma
NCT00290433Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2003
- Primary completion
- Jul 2015
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in peripheral T-cell lymphoma (PTCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: 3 Year Progression-Free Survival Rate. Started Sep 2003; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00290433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290433.